Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Minerva Neurosciences Inc NERV

Healthcare Biotechnology
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NERV)

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire 4 days ago

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

GlobeNewswire February 27, 2024

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

GlobeNewswire February 22, 2024

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

GlobeNewswire November 7, 2023

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

GlobeNewswire August 1, 2023

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

GlobeNewswire June 28, 2023

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

GlobeNewswire May 15, 2023

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

GlobeNewswire May 10, 2023

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

GlobeNewswire May 8, 2023
View More News ››

Opinion & Analysis (NDAQ:NERV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NERV)

Regulatory Setback For Minerva Neurosciences' Schizophrenia

JUST IN: $NERV Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data...
whytestocks - February 27, 2024
View more Bullboard ››

Ciscom Corp.

Ciscom Corp.

Ciscom Corp. is a Canada-based holding (roll-up) company. The Company is acquiring and managing companies in the information ...
View More »